Work

Supplementary Figures 1-9 from Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figures 1-9. Sabutoclax has greater efficacy than ABT-737. (S1) Sabutoclax causes a G1-S phase cell cycle arrest. (S2) Pancreatic cancer cells exhibit varying levels of sensitivity to Minocycline. (S3) Sabutoclax and Minocycline induce cytotoxicity in PANC-1 cells that is reversed with zVAD. (S4) Sabutoclax and Minocycline show synergy. Combination index (CI) values for the combination of Sabutoclax and Minocycline in MIA PaCa-2 cells. (S5) The cytotoxicity induced by Sabutoclax and Minocycline is caspase-dependent and dependent upon loss of Stat3 activation. (S6) Sabutoclax and Minocycline reduce tumor growth in a subcutaneous xenograft model of pancreatic cancer. (S7) Tumors from Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt and Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox mice overexpress Mcl-1 and show sensitivity to Sabutoclax and Minocycline. (S8) Tumors from KPC (Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox )mice treated with Sabutoclax and Minocycline show decreased Stat3 activation. (S9)

DOI: 10.1158/0008-5472.22405650

Authors: Bridget A. Quinn, Rupesh Dash, Siddik Sarkar, Belal Azab, Praveen Bhoopathi, Swadesh K. Das, Luni Emdad, Jun Wei, Maurizio Pellecchia, Devanand Sarkar, Paul B. Fisher

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361874497

Cites:

Cited by:

Related to: 10